Navigation Links
MannKind Submits NDA for AFRESA for Treatment of Diabetes
Date:3/16/2009

VALENCIA, Calif., March 16 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) requesting approval of AFRESA(R) (insulin monomer human [rDNA origin]) Inhalation Powder and the AFRESA(R) Inhaler for the treatment of adults with type 1 or type 2 diabetes mellitus for the control of hyperglycemia.

There are 23.6 million people in the United States, or 8% of the population, who have diabetes. Diabetes currently affects 246 million people worldwide and is expected to affect 380 million by 2025. Each year, a further 7 million people develop diabetes and 3.8 million people succumb to the disease.

AFRESA is an ultra rapid-acting insulin. It is a drug-device combination product, consisting of AFRESA Inhalation Powder pre-metered into single unit dose cartridges and the AFRESA Inhaler as the delivery device for oral inhalation. However, the feature that distinguishes AFRESA from all other insulin products is not the route of administration - it is the pharmacokinetic profile. The large surface area of the lung provides unique access to the circulatory system. The pH-sensitive AFRESA particles immediately dissolve upon contact with the lung surface, releasing insulin monomers that rapidly enter the bloodstream. AFRESA achieves peak insulin levels within 12-14 minutes of administration, effectively mimicking the release of meal-time insulin observed in healthy individuals, but which is absent or impaired in patients with diabetes.

The NDA submission is based on an extensive clinical program, involving 44 completed studies and five ongoing studies at the time of submission. The clinical program included over 5,300 patients. More than 2,450 subjects with type 1 or type 2 diabetes were randomly assig
'/>"/>

SOURCE MannKind Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. MannKind Agrees with Pfizer on the Purchase of Frankfurt Insulin Manufacturing Plant
2. MannKind Corporation to Hold Fourth Quarter Financial Results Conference Call on February 17, 2009
3. MannKind to Present at the 11th Annual Biotechnology Industry Organization BIO CEO & Investor Conference
4. SemBioSys receives US$2.5 million from option agreement with MannKind for plant-produced insulin
5. MannKind to Present at the Piper Jaffray 20th Annual Health Care Conference
6. MannKind to Present at the Rodman & Renshaw Annual Global Investment Conference
7. MannKind Corporation to Hold Third Quarter Financial Results Conference Call on November 5, 2008
8. MannKind Unveils Proposed Trade Name at Dedication of Danbury Manufacturing Facility
9. MannKind to Present at the UBS Global Life Sciences Conference
10. MannKind Corporation Reports Second Quarter Financial Results
11. MannKind Corporation to Hold Second Quarter Financial Results Conference Call on August 11, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014  United Therapeutics Corporation (NASDAQ: ... MDT ) has submitted a pre-market ... Administration (FDA) for the use of Medtronic,s SynchroMed ... a newly developed catheter) for use with United ... to patients with pulmonary arterial hypertension.   ...
(Date:12/24/2014)... , Dec. 24, 2014   BioLife Solutions , ... manufacturer and marketer of proprietary clinical grade hypothermic ... precision thermal shipping products for cells and ... will hold its 2015 Annual Meeting of Stockholders on ... the expected date for the Annual Meeting represents a ...
(Date:12/24/2014)... 2014 Earlier this year in a ... director of the Adult Stem Cell Technology Center, LLC ... and under appreciated unique property of adult tissue stem ... Cells: Misunderstood in the Past, Important for the Future,” ... He gave the address at the 4th World ...
(Date:12/24/2014)... According to Ross Selinger, President of ... Global, the national office market continues to be strong, driven ... evidenced by the third quarter’s surprising 3.9% GDP, unemployment decreasing ... costs have held inflation down and the Fed is keeping ... market remaining soft. , This solid economic news is having ...
Breaking Biology Technology:United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3
... First 9 Months Compared with Fiscal 2007,Net Income To ... MOUNTAIN VIEW, Calif., Jan. 24 Pharsight,Corporation (Nasdaq: ... strategic,services designed to optimize clinical drug development, today announced,financial ... December 31,2007. Revenue for the third quarter was $7.4 ...
... Call and Webcast Scheduled for Tuesday, February 5, ... NBIX ) announced today that the Company will report ... Nasdaq market closes,on Tuesday, February 5, 2008. Neurocrine will ... its financial results and provide a Company,update Tuesday afternoon, ...
... /PRNewswire-FirstCall/,-- Cephalon, Inc., (Nasdaq: CEPH ) announced ... Human Use (CHMP) of the European,Medicines Agency has ... buccal tablet pain medication. In March 2007, Cephalon,submitted ... treatment of,breakthrough pain in adult cancer patients who ...
Cached Biology Technology:Pharsight Achieves $7.4 Million in Quarterly Revenue 2Pharsight Achieves $7.4 Million in Quarterly Revenue 3Pharsight Achieves $7.4 Million in Quarterly Revenue 4Pharsight Achieves $7.4 Million in Quarterly Revenue 5Pharsight Achieves $7.4 Million in Quarterly Revenue 6Pharsight Achieves $7.4 Million in Quarterly Revenue 7Pharsight Achieves $7.4 Million in Quarterly Revenue 8Pharsight Achieves $7.4 Million in Quarterly Revenue 9Pharsight Achieves $7.4 Million in Quarterly Revenue 10Pharsight Achieves $7.4 Million in Quarterly Revenue 11Pharsight Achieves $7.4 Million in Quarterly Revenue 12Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year End 2007 Financial Results 2Cephalon's EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain 2Cephalon's EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain 3Cephalon's EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain 4
(Date:12/17/2014)... , Dec. 15, 2014 Research and Markets ... addition of the "Samsung Galaxy S5 - ... report to their offering. ... totally different sensing technology than the iPhone 5S, ... sensor in its product. The Galaxy ...
(Date:12/17/2014)... , Dec. 15, 2014  HITLAB SM ... Clinical Practices (GCP) audit to confirm its adherence ... regulations. This accomplishment enables HITLAB to conduct regulated ... the highest principles for patient safety and research ... global healthcare access, quality, and delivery with innovative ...
(Date:12/17/2014)... 2014 Research and Markets ( ... "Global Chemical Sensor Market 2015-2019" report ... http://photos.prnewswire.com/prnh/20130307/600769 One major trend upcoming ... medical sensors in biomedical applications. Chemical sensors help ... correct diagnosis during surgical procedures. The Global Chemical ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
... A breakthrough in human stem cell research, producing embryonic-like ... the development of treatments for life-threatening illnesses, injuries and ... experts from the University of Texas Medical Branch and ... researchers and physicians with an ethical and reliable source ...
... rise, and the loss of sand dune plant habitats" ... to better understand the impacts of development and coastal ... the ever-shrinking strip of habitat between land and the ... simulated varying levels of sea-level rise to understand the ...
... the body, a virus such as HIV invades body cells ... Once inside the cell, the invading microbe's genetic material takes ... more copies of the virus, which then spill out to ... that once a virus begins fusing with a cell's membrane, ...
Cached Biology News:Insight into the processes of 'positive' and 'negative' learners 2Squeezing out dune plants 2Several minute intermediate stage in virus-cell fusion discovered; opportunity for drug development 2Several minute intermediate stage in virus-cell fusion discovered; opportunity for drug development 3
B-FABP (FL-132)...
... Varioskan is a high performance spectral ... and incubator. With the advanced SkanIt ... reliability for drug discovery assay development. ... fluorescence intensity, time-resolved fluorescence and photometric ...
... Lambda Protein Phosphatase ( ... protein phosphatase with activity ... and tyrosine residues. It ... product of the ORF221 ...
Strip Removal Tool 25/Box...
Biology Products: